Navigation Links
Cystic Fibrosis Foundation Launches National Cycling Series to Benefit Critical Research and Care
Date:5/3/2010

Eurand Donates $300,000 as Title Sponsor of ZENPEP(R) CF Cycle for Life

BETHESDA, Md., May 3 /PRNewswire-USNewswire/ -- Thousands of cyclists will take to the streets this summer and fall as the Cystic Fibrosis Foundation launches a new cycling tour in 18 cities across the country to support research to find new therapies and a cure for cystic fibrosis. The tour series, known as ZENPEP® CF Cycle for Life, begins in San Francisco on June 26.

The event's title sponsor is Eurand N.V., a global specialty pharmaceutical company, which makes ZENPEP® (pancrelipase) Delayed-Release capsules, a pancreatic enzyme replacement therapy.

"Eurand is proud to serve as national sponsor of the inaugural ZENPEP CF Cycle for Life series," said Ruth Thieroff-Ekerdt, M.D., Eurand's Chief Medical Officer. "We're pleased to support the Cystic Fibrosis Foundation in its efforts to advance life-saving medical research for CF and develop therapies that have the potential to add decades of life for those with this devastating disease."

The touring series offers cyclists several mileage options – 30 or 65 miles, as well as scenic routes, training rides, cycling "how-to" clinics, safety inspections and lots of day-of support and activities.

"We are grateful to Eurand for joining our team and supporting our effort to bring cycling enthusiasts to the fight against cystic fibrosis," said C. Richard Mattingly, executive vice president and chief operating officer of the Cystic Fibrosis Foundation. "The company's generous support means we can expand our already robust drug development effort as we aggressively invest in new ways to fight and eradicate this horrific disease."

Cycling tours will take place this year in: Atlanta, Ga., Baton Rouge, La., Boston, Mass., Charleston, S.C., Denver, Colo., Dayton, Ohio, Grand Rapids, Mich., Hartford, Conn., Jacksonville, Fla., Portland, Ore., Malvern, Pa., Peoria, Ill., Phoenix, Ariz., San Diego, Calif., San Francisco, Calif., Seattle, Wash., Tampa, Fla., and Tyler, Texas.

ZENPEP is an FDA-approved pancreatic enzyme therapy used for treatment of exocrine pancreatic insufficiency from CF or other conditions. More than 90 percent of people with cystic fibrosis take enzyme supplements to help absorb vitamins and nutrients, and could not survive without them.

For more information about ZENPEP CF Cycle for Life, visit

http://www.cff.org/aboutCFFoundation/PressRoom/2010PressReleases/05-03-CF-Foundation-Launches-Cycling-Series.cfm

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. For more information, visit www.cff.org.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles and taste-masking orally disintegrating tablet (ODT) formulations. Eurand is a global company with facilities in the U.S. and Europe. For more information, visit Eurand's website at www.eurand.com.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis
2. PARI Pharmas Altera Delivers Gileads Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa
3. CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis
4. Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis
5. Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
6. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
7. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
8. Cystic Fibrosis - Orphan Drug Designation for Innovative Treatment Against Lung Infections by Axentis Pharma AG
9. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
10. Nanoemulsion Kills Highly Resistant Bacteria Found in Patients With Cystic Fibrosis
11. PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Summary Breast cancer, a malignant neoplasm, ... common cancer in women worldwide, accounting for 16% of ... number of women diagnosed with breast cancer has increased ... deaths has declined due to earlier diagnosis and better ... in the past four decades, especially with increasing usage ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
(Date:2/4/2016)... Ohio, Feb. 4, 2016 Mettler-Toledo International Inc. ... for 2015.  Provided below are the highlights: ... quarter compared with the prior year.  Reported sales decreased ... the quarter. , Net earnings per diluted share ... the prior- year period.  Adjusted EPS was $4.65, an ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active ... Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division ... completed his first three-year term as chief and began a second three-year term in ...
(Date:2/5/2016)... , ... February 05, 2016 , ... US Sports ... Studio in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is ... just one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her ...
(Date:2/5/2016)... ... ... The American public tends to feel uncomfortable about drinking recycled waste water ... well water. The recent experience with lead contaminated water in Flint, Michigan, according to ... increasing public acceptance of recycled waste water as drinking water. , The Flint ...
(Date:2/5/2016)... ... , ... Give To Cure today announced that it is working ... To Cure’s campaign that is crowdfunding clinical trials to help find cures faster for ... a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point Consulting, a leading ... Software & Services for HIT Implementation Support & Staffing report with an outstanding ... performance by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 ...
Breaking Medicine News(10 mins):